HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Erasmus, J. J. Articles by Connolly, J. E. Search for Related Content PubMed PubMed Citation Articles by Erasmus, J. J. Articles by Connolly, J. E. Related Collections Chest Radiology Related Article

Solitary Pulmonary Nodules: Part II. Evaluation of the Indeterminate Nodule¹

¹ From the Department of Radiology, Duke University Medical Center, Erwin Road, Durham, NC 27710 (J.J.E., H.P.M.), and the Department of Radiology, Rush Presbyterian Medical Center, Chicago, Ill (J.E.C.). Presented as a scientific exhibit at the 1998 RSNA scientific assembly. Received February 19, 1999; revision requested March 29 and received June 9; accepted June 10. Address reprint requests to J.J.E.

Various strategies may be used to evaluate indeterminate solitary pulmonary nodules. Growth rate assessment is an important and cost-effective step in the evaluation of these nodules. Clinical features (eg, patient age, history of prior malignancy, presenting symptoms, smoking history) can be useful in suggesting the diagnosis and aiding in management planning. Bayesian analysis allows more precise determination of the probability of malignancy (pCa). Decision analysis models suggest that the most cost-effective management strategy depends on the pCa for a given nodule. At contrast material–enhanced computed tomography, nodular enhancement of less than 15 HU is strongly predictive of a benign lesion, whereas enhancement of more than 20 HU typically indicates malignancy. At 2-[fluorine-18]fluoro-2-deoxy-d-glucose (FDG) positron emission tomography, lesions with low FDG uptake are typically benign, whereas those with increased FDG uptake are typically malignant. Results of transthoracic needle aspiration biopsy influence management in approximately 50% of cases and, in indeterminate lesions with a pCa between 0.05 and 0.6, is the best initial diagnostic procedure. It is optimally used in peripheral nodules and has been reported to establish a benign diagnosis in up to 91% of cases. Although there is no one correct management approach, the ability to distinguish benign from malignant solitary pulmonary lesions has improved with the use of these strategies.

Index Terms: Fluorine, radioactive, 60.12163 • Lung, CT, 60.1211 • Lung, diseases, 60.281, 60.332 • Lung, nodule, 60.11, 60.1211, 60.12163, 60.281, 60.332 • Lung, radionuclide studies, 60.12163

Related Article

Solitary Pulmonary Nodules: Part I. Morphologic Evaluation for Differentiation of Benign and Malignant Lesions

Jeremy J. Erasmus, John E. Connolly, H. Page McAdams, and Victor L. Roggli
RadioGraphics 2000 20: 43-58. [Abstract] [Full Text] [PDF]

This article has been cited by other articles:

				F. Wang, Z. Wang, W. Yao, H. Xie, J. Xu, and L. Tian Role of 99mTc-Octreotide Acetate Scintigraphy in Suspected Lung Cancer Compared with 18F-FDG Dual-Head Coincidence Imaging J. Nucl. Med., September 1, 2007; 48(9): 1442 - 1448. [Abstract] [Full Text] [PDF]

				Y. J. Jeong, C. A. Yi, and K. S. Lee Solitary Pulmonary Nodules: Detection, Characterization, and Guidance for Further Diagnostic Workup and Treatment Am. J. Roentgenol., January 1, 2007; 188(1): 57 - 68. [Abstract] [Full Text] [PDF]

				T. Bunyaviroch and R. E. Coleman PET Evaluation of Lung Cancer J. Nucl. Med., March 1, 2006; 47(3): 451 - 469. [Full Text] [PDF]

				J. E. Heffner, K. Highland, and L. K. Brown A Meta-analysis Derivation of Continuous Likelihood Ratios for Diagnosing Pleural Fluid Exudates Am. J. Respir. Crit. Care Med., June 15, 2003; 167(12): 1591 - 1599. [Full Text] [PDF]

				X. Varas, J. H. Leborgne, F. Leborgne, J. Mezzera, S. Jaumandreu, and F. Leborgne Revisiting the Mammographic Follow-Up of BI-RADS Category 3 Lesions Am. J. Roentgenol., September 1, 2002; 179(3): 691 - 695. [Abstract] [Full Text] [PDF]

				T. Nawa, T. Nakagawa, S. Kusano, Y. Kawasaki, Y. Sugawara, and H. Nakata Lung Cancer Screening Using Low-Dose Spiral CT* : Results of Baseline and 1-Year Follow-up Studies Chest, July 1, 2002; 122(1): 15 - 20. [Abstract] [Full Text] [PDF]

				C. Schaefer-Prokop and M. Prokop New imaging techniques in the treatment guidelines for lung cancer Eur. Respir. J., February 1, 2002; 19(35_suppl): 71S - 83s. [Abstract] [Full Text] [PDF]

				A. Imdahl, S. Jenkner, I. Brink, E. Nitzsche, E. Stoelben, E. Moser, and J. Hasse Validation of FDG positron emission tomography for differentiation of unknown pulmonary lesions Eur. J. Cardiothorac. Surg., August 1, 2001; 20(2): 324 - 329. [Abstract] [Full Text] [PDF]

				P. M. Boiselle, A. Ernst, and D. D. Karp Lung Cancer Detection in the 21st Century: Potential Contributions and Challenges of Emerging Technologies Am. J. Roentgenol., November 1, 2000; 175(5): 1215 - 1221. [Full Text] [PDF]